Organogenesis Stock Surges Amid $130M Preferred Stock Financing and Major Share Buyback
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Organogenesis Holdings Inc. (NASDAQ: ORGO) is a Canton, Massachusetts-based public company specializing in regenerative medicine. Since its founding in 1985, the company has offered a portfolio of bioactive and acellular biomaterials for advanced wound care, surgical biologics, and sports medicine. On November 7, 2025, its stock closed at $5.12, reflecting a 31.62% increase for the day with a trading volume of 826,977 shares.
Corporate Structure and Workforce
Organogenesis operates in the healthcare sector under the drug manufacturers – other industry classification. The company employs between 501 and 1,000 individuals across its research, manufacturing, and commercial functions. Major shareholders as of June 24, 2025, include Alan A. Ades, who holds 17.6% of Class A common stock, and Albert Erani, who holds 14.1%, indicating concentrated ownership and potential influence over corporate governance.
Regenerative medicine by Anshita Nair
Recent Developments and News
- November 12, 2024 – $130 Million Private Placement
Organogenesis entered into a subscription agreement with Avista Healthcare Partners for the sale of Series A Convertible Preferred Stock, raising $130 million in gross proceeds prior to fees. The intended use of proceeds includes funding for clinical programs, commercial expansion, working capital, debt repayment, and general corporate purposes. Approximately $23.5 million was allocated to repurchase 7.42 million shares of Class A common stock at a price of $3.1597 per share. Additionally, Garrett Lustig of Avista was appointed to the board of directors effective November 12, 2024. - Q3 2025 Earnings Report
In early November 2025, Organogenesis released its third-quarter 2025 results, detailing operational progress in the advanced wound care and surgical markets. - SEC Schedule 13D/A Amendments
Amendments filed on January 3, January 13, and June 26, 2025, report changes in beneficial ownership stakes by key executives, reflecting active engagement by major shareholders.
Financial and Strategic Analysis
Organogenesis' recent trailing-twelve-month metrics:
| Metric | Value |
|---|---|
| Revenue | $429.5 million |
| Gross Margin | 74.6% |
| Net Margin | –1.9% |
| EBITDA | $3.17 million |
| EPS (TTM) | –$0.13 |
| Debt/Equity (MRQ) | 0.36× |
| Market Cap | $645 million |
| 52-Week Range | $2.61 – $6.71 |
The November 2024 preferred-stock financing is expected to improve the company’s liquidity and financial flexibility. Preferred shares carry an 8% cumulative annual dividend and are convertible at $3.79 per share, which is a 20% premium to the volume-weighted average price prior to the agreement. Conversion rights are limited to 19.99% of the outstanding common shares until shareholder approval is obtained.
Market Position and Industry Context
Organogenesis competes in the regenerative medicine sector alongside companies focused on developing cellular and tissue-based products. Its advanced wound care portfolio—highlighted by bioactive skin substitutes—addresses a variety of chronic and acute wounds, while its surgical biologics for orthopedics and spine diversify revenue streams. With high gross margins and ongoing investments in clinical development, the company is positioned to expand its market share, particularly in demographics with aging populations and an increasing prevalence of diabetic and vascular ulcers.
tl;dr
Organogenesis shares increased by 31.62% on November 7, 2025, amid substantial trading volume. The $130 million Series A preferred-stock placement on November 12, 2024, strengthened the balance sheet and facilitated a $23.5 million share repurchase. Major stakeholders filed three Schedule 13D/A amendments through June 26, 2025, indicating concentrated governance. Upcoming developments include the execution of clinical programs funded by recent capital and the next earnings release, currently estimated for February 25, 2026.